1 Wakwaya Y, Brown KK. Idiopathic pulmonary fibrosis: Epidemiology, diagnosis andoutcomes[J]. Am J Med Sci, 2019, 357(5): 359-369.
2 李青原, 冯 同, 邱雪琴, 等. 迷迭香提取物防治肺纤维化研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(6): 908-911.
3 Amariei DE, Dodia N, Deepak J, et al. Combined pulmonary fibrosis and emphysema: Pulmonary function testing and a pathophysiology perspective[J]. Medicina(Kaunas), 2019, 55(9): 580.
4 Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease[J]. N Engl J Med, 2019, 380(26): 2518-2528.
5 廖太阳, 杨 楠, 张 力, 等. 白杨素对离体培养致炎大鼠软骨细胞凋亡及内质网应激GRP78/PERK/CHOP通路的影响[J]. 中国病理生理杂志, 2022, 38(12): 2197-2204.
6 Furmanik M, Van Gorp R, Whitehead M, et al. Endoplasmic reticulum stress mediates vascular smooth muscle cell calcification via increased release of Grp78(Glucose-Regulated Protein, 78 kDa)-loaded extracellular vesicles[J]. Arterioscler Thromb Vasc Biol, 2021, 41(2): 898-914.
7 Le QG, Kimata Y. Multiple ways for stress sensing and regulation of the endoplasmic reticulum-stress sensors[J]. Cell Struct Funct, 2021, 46(1): 37-49.
8 余华军, 吴 尚, 黄 慧, 等. 内窥镜引导气管注入博来霉素建立小鼠肺纤维化模型[J]. 实验动物与比较医学, 2019, 39(2): 94-98.
9 吕紫薇, 黄 凯, 甘文华, 等. 吡非尼酮和尼达尼布抑制博来霉素诱导的小鼠肺纤维化药效比较[J]. 中国病理生理杂志, 2020, 36(1): 112-118.
10 李婉莹, 高慧英, 刘金芳, 等. 2-吲哚啉酮衍生物预防给药对放射性肺纤维化模型小鼠的防护作用[J]. 中国药理学与毒理学杂志, 2019, 33(12): 24-31.
11 Rago F, Melo EM, Kraemer L, et al. Effect of preventive or therapeutic treatment with angiotensin 1-7 in a model of bleomycin-induced lung fibrosis in mice[J]. J Leukoc Biol, 2019, 106(3): 677-686.
12 Piao C, Zhuang C, Ko MK, et al. Pulmonary delivery of a recombinant RAGE antagonist peptide derived from high-mobility group box-1 in a bleomycin-induced pulmonary fibrosis animal model[J]. J Drug Target, 2022, 30(7): 792-799.
13 Jia L, Sun P, Gao H, et al. Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-β1/Smad2/3 pathway[J]. J Pharm Pharmacol, 2019, 71(6): 1017-1028.
14 崔立坤, 姚 静, 辛 勤, 等. 山姜素对角叉菜胶诱导的小鼠急性炎症的抗炎作用及机制研究[J]. 中国临床药理学杂志, 2019, 35(19): 2276-2279.
15 Glass DS, Grossfeld D, Renna HA, et al. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches[J]. Respir Investig, 2020, 58(5): 320-335.
16 Yue Z, Zhou R, Li Q, et al. Pulmonary fibrosis induced by CdSe nanorods and the therapy with modified procyanidinere[J]. Toxics, 2022, 10(11): 673.
17 Gad ES, Salama AAA, El-Shafie MF, et al. The anti-fibrotic and anti-inflammatory potential of bone marrow-derived mesenchymal stem cells and nintedanib in bleomycin-induced lung fibrosis in rats[J]. Inflammation, 2020, 43(1): 123-134.
18 Snijder J, Peraza J, Padilla M, et al. Pulmonary fibrosis: a disease of alveolar collapse and collagen deposition[J]. Expert Rev Respir Med, 2019, 13(7): 615-619.
19 Borok Z, Horie M, Flodby P, et al. Grp78 loss in epithelial progenitors reveals an age-linked role for endoplasmic reticulum stress in pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2020, 201(2): 198-211.
20 Bahri S, Ali RB, Abdennabi R, et al. Industrial elimination of essential oils from rosmarinus officinalis: In support of the synergic antifibrotic effect of rosmarinic and carnosic acids in bleomycin model of lung fibrosis[J]. Nutr Cancer, 2020: 1-12.
21 Pan T, Zhou Q, Miao K, et al. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis[J]. Theranostics, 2021, 11(3): 1192-1206.